Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2019

View Archived Issues

Discovery of novel HCV inhibitor L-0909

GlaxoSmithKline presents the discovery of GSK-778

Epigenetic inactivation of CELF2 associated with shorter overall survival in breast cancer

Phase II results support further study of AAV2-REP1 gene therapy in patients with choroideremia

Novel type of galactosemia caused by GALM gene mutations revealed

Study partially rehabilitates telomerase in cancer

Rock-paper-synthetic biology

Genentech describes lead small-molecule IRAK-4 inhibitors

Asthma symptoms have distinct origins, common target

PRC2 inhibitors patented by Shanghai Institute of Materia Medica, Suzhou Suplead Life Sciences

Bristol-Myers Squibb discovers STING agonists

FDA approves Ofev for interstitial lung disease associated with scleroderma

Phase I results of inhaled 5-azacytidine for the treatment of advanced non-small cell lung cancer

Enanta Pharmaceuticals discloses new farnesoid X receptor agonists

New PD-1/PD-L1 interaction inhibitors described by Gilead Sciences

AstraZeneca presents arginase-1 and arginase-2 inhibitors

Boehringer Ingelheim, Hydra Biosciences patent TRPC6 antagonists

Vicore completes phase I study of angiotensin II type 2 receptor agonist C-21

AstraZeneca reports phase III data on Imfinzi in previously untreated extensive-stage SCLC

Bristol-Myers Squibb designs RORgammaT inverse agonists showing biologic-like efficacy

Theravance reports first-in-human data on TD-8236 for inflammatory lung disease

Acadia's phase III study of pimavanserin in dementia-related psychosis meets primary endpoint

Passage Bio licenses gene therapy program for CMT2A from Penn

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...